William Meury

Chief Executive Officer, President & Director, Incyte

Search every verified William Meury interview, podcast appearance, and on-the-record quote — each transcript cross-checked by AI and human review to confirm speaker identity. In a January 2026 interview on CNBC's "Fast Money," Incyte CEO Bill Meury discussed the company's strategy to address the anticipated loss of revenue from its drug Jakafi, which was projected to generate around $3 billion in 2025. Meury stated that the company had advanced seven pipeline programs in 2025, supported by 14 phase three trials, and that he believed there was now greater visibility into the company's growth trajectory. He described the development of three targeted therapies for blood cancer as the "central identity" of the company, noting that no targeted treatments currently exist for that condition. Meury also identified two solid tumor oncology programs—a G12D inhibitor for pancreatic cancer and a TGF beta by PD1 bispecific for colorectal cancer—as "outlier opportunities." Meury stated that Incyte's balance sheet, which he said would grow to roughly $5 billion by the end of 2026, provided "firepower" for strategic M&A. He indicated that any acquisitions would be used to "strengthen or extend the core" rather than to fill a revenue gap, and that the company would look for assets with a high fit to Incyte's capabilities that could produce durable revenue and cash flow. When asked about using a priority review voucher from the FDA to accelerate approvals, Meury said the company was evaluating all options for accelerating development and approval.